STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

UTHR Rule 144 Notice: Martine Rothblatt proposes 4,000-share sale

Filing Impact
(Low)
Filing Sentiment
(Neutral)
Form Type
144

Rhea-AI Filing Summary

UNITED THERAPEUTICS (UTHR) reported a Rule 144 notice disclosing a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,807,320. The filing shows these shares were acquired on 03/15/2016 under an executive deferred compensation arrangement from Martine Rothblatt, and payment was made by exercising vested options with shares used for payment. The issuer has 45,230,000 shares outstanding, so the single proposed block equals roughly 0.009% of outstanding stock. The filing also itemizes prior open-market sales by the same person totaling 80,000 shares over the past three months, generating multi‑million dollar proceeds on multiple dates.

Positive

  • Transparent disclosure of a planned insider sale under Rule 144, specifying broker, acquisition date, and payment method
  • Detailed history of past open-market sales (totaling 80,000 shares) provides context for recent dispositions

Negative

  • Insider selling activity continued over recent months (80,000 shares sold), which some investors may view unfavorably despite immaterial size
  • No information in this filing about remaining insider holdings after the recent sales, limiting assessment of post-sale ownership concentration

Insights

Insider disclosed routine sales; size is immaterial to float.

The notice shows a planned sale of 4,000 common shares valued at $1,807,320, acquired in 2016-03-15 via executive deferred compensation and option exercise. With 45,230,000 shares outstanding, the single proposed sale is a very small fraction of the company’s share count.

Recent activity lists 80,000 shares sold in the last three months, producing multi‑million dollar proceeds across many dates; this trading history is transparent and consistent with scheduled or opportunistic dispositions. Monitor quarterly filings for any change in insider ownership trends over the next 3 months.

Disclosure follows Rule 144 mechanics and includes source and payment details.

The filing specifies the acquisition date, nature of acquisition (executive deferred compensation), and that payment involved exercised vested options paid in common shares, which clarifies transfer basis for compliance purposes. The filer also affirms absence of undisclosed material nonpublic information as required by the form.

Investors interested in insider intentions should watch proxy and Form 4 disclosures and any amended 144 filings within 30 days for updates to planned sale timing.

144: Filer Information

144: Issuer Information

144: Securities Information



Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold


* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.



Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

144: Remarks and Signature

FAQ

What did the UNITED THERAPEUTICS (UTHR) Form 144 disclose?

The filing disclosed a proposed sale of 4,000 common shares through TD Securities (USA) LLC with an aggregate market value of $1,807,320.

Who is the seller in the UTHR Form 144 filing?

The seller is Martine Rothblatt, who acquired the disclosed shares on 03/15/2016 via an executive deferred compensation arrangement and exercised vested options.

How much of UTHR’s outstanding stock does the proposed sale represent?

The proposed 4,000-share sale represents approximately 0.009% of the issuer’s 45,230,000 shares outstanding.

How many shares did the insider sell in the past three months?

The filing lists sales totaling 80,000 shares over the past three months, generating multi‑million dollar gross proceeds on multiple dates.

Does the filing indicate any material nonpublic information?

By signing the form, the filer represents they do not know any material adverse information about the issuer that has not been publicly disclosed.
United Therapeutics Corp.

NASDAQ:UTHR

UTHR Rankings

UTHR Latest News

UTHR Latest SEC Filings

UTHR Stock Data

21.03B
42.14M
1.77%
99.51%
5.97%
Drug Manufacturers - Specialty & Generic
Pharmaceutical Preparations
Link
United States
SILVER SPRING